A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/16/2002	EP1248654A2 Intra-tumoral administration of il-12 encoding nucleic acid molecules
10/16/2002	EP1248645A1 Novel chimeric proteins and methods for using the same
10/16/2002	EP1248644A1 Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this
10/16/2002	EP1248635A1 Antisense modulation of glycogen synthase kinase 3 alpha expression
10/16/2002	EP1248634A1 Antisense modulation of mekk2 expression
10/16/2002	EP1248625A2 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
10/16/2002	EP1248612A1 Novel compounds and compositions as protease inhibitors
10/16/2002	EP1248610A2 Use of at least a fatty ester for preparing a composition designed to inhibit 5-alpha-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive
10/16/2002	EP1248552A1 Pp14 fusion proteins and methods for making and using the same
10/16/2002	EP1248517A2 Clonal propagation of primate offspring by embryo splitting
10/16/2002	EP1206574A4 Guanidinium functionalized oligomers and methods
10/16/2002	EP1140065A4 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/16/2002	EP1100528B1 Use of novel agents inducing cell death in synergy with interferons
10/16/2002	EP0998279B1 Pharmaceutical injection solution containing taxol
10/16/2002	EP0975632B1 Alkaloid halide salts of swainsonine and methods of use
10/16/2002	EP0944596B1 1-acryloylindoline derivatives and their use as prodrugs of anticancer agents
10/16/2002	EP0927161B1 Substituted cyclic amine metalloprotease inhibitors
10/16/2002	EP0920434B1 Bis-platinum complexes with polymethylene derivatives as ligands having antitumor activity
10/16/2002	EP0877605B1 Solid instant-release forms of administration and process for producing the same
10/16/2002	EP0672128B1 Stem cell proliferation factor
10/16/2002	EP0639225B1 New polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology
10/16/2002	EP0619742B1 Transfection of lung via aerosolized transgene delivery
10/16/2002	CN1375004A Methods and compsotions for inhibiting the function of polynucleotide sequences
10/16/2002	CN1374969A FAP-activated anti-tumor compounds
10/16/2002	CN1374961A Azepinoindole derivatives, the production and use thereof
10/16/2002	CN1374960A Novel integrain receptor antagonists
10/16/2002	CN1374955A Oxa-and thiazole derivatives useful as antidiabetic and antibesity agents
10/16/2002	CN1374954A New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents cnotaining these compounds
10/16/2002	CN1374950A Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
10/16/2002	CN1374872A Stabilization of macrolides
10/16/2002	CN1374870A Treatment of intermediate-and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
10/16/2002	CN1374869A Use of CASB 616 polypeptides and polynucleotides for cancer treatment
10/16/2002	CN1374864A Prevention and therapeutic agents for cancer
10/16/2002	CN1374863A Bicyclic antagonists selective for the alpha beta integrin
10/16/2002	CN1374858A For mulations for parenteral use of estramustine phosphate with improved pharmacological properties
10/16/2002	CN1374857A Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
10/16/2002	CN1374323A Giant-web bombinator antineoplastic protein and its prepn and gene
10/16/2002	CN1374320A HAb18G(/CD147) peptide agonist and its prepn and use
10/16/2002	CN1374318A Natural dissociation essence gamma gene and antineoplastic active polypeptide dissociation essence-gamma
10/16/2002	CN1374316A Macrocyclic target specific antisense nucleic acid compound
10/16/2002	CN1374308A Antineoplastic active compound nitrene-phin and its prepn
10/16/2002	CN1374288A Gronwell naphthaquinone derivative and its application in preparing anticancer medicine
10/16/2002	CN1374132A Prepn of core-shell type nano compound hydroxyapatiti-liposome particle
10/16/2002	CN1374123A Ningtongling as a pain killer
10/16/2002	CN1374120A Pseudozoogloea adjuvant and its prepn and application
10/16/2002	CN1374108A Cancer and tumor treating capsule and its prepn
10/16/2002	CN1374105A Cancer treating Chinese herbal medicine powder
10/16/2002	CN1374090A Application of active biologics prepared with spinal cord, brains, liver and blood of turtle and/or tortoise and animal penis in preparing medicine
10/16/2002	CN1374088A Bcl-2 gene antisense nucleic acid medicine for resisting leukemia and tumor drug-fast
10/16/2002	CN1374084A Lauryl piperazine, lauryl diethanolamine and the application of their derivatives in extracorporeal marrow purification
10/16/2002	CN1092640C Imides as PDE III, PDE IV and TNF inhibitors
10/16/2002	CN1092523C Lung cancer treating Chinese medicine preparation and its preparing method
10/16/2002	CA2406161A1 2-guanidino-4-arylquinazolines as nhe-3 inhibitors
10/15/2002	US6465715 Dna fragments from the promoter region of the c. elegans ul6 gene which are capable of functioning as promoters directing gene expression in the excretory cell of c. elegans are provided and also expression vectors and transgenic c. elegans
10/15/2002	US6465687 Thyroid receptor ligands and method
10/15/2002	US6465686 Halogenated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/15/2002	US6465660 Isoindoloindolone compounds
10/15/2002	US6465522 Anthraquinone anticancer drugs
10/15/2002	US6465518 2-amino-5-fluoro-6-(1-iminoethylamino)-hept-4-enoic acid, for example; treating or preventing various causes of inflammation
10/15/2002	US6465512 Leukemic cell growth inhibiting method
10/15/2002	US6465507 Antitumor agents
10/15/2002	US6465503 Selective urokinase inhibitors
10/15/2002	US6465497 Arylthiazolidinedione derivatives
10/15/2002	US6465495 Preparation of pyridone-based phosphotyrosine mimetics and uses thereof
10/15/2002	US6465487 Inhibition of membrane-associated viral replication
10/15/2002	US6465474 Treatment of such as osteoarthitis, rheumatoid arthritis, prevention or arrest of tumor growth and metastasis, corneal ulceration, lack of corneal healing, macular degeneration, periodontal disease, gingivitis
10/15/2002	US6465468 Hydroxamic and carboxylic acid derivatives
10/15/2002	US6465449 Heteroaromatic bicyclic derivatives useful as anticancer agents
10/15/2002	US6465448 Treating tumors resistant to temozolomide alone
10/15/2002	US6465447 Solvent extraction, concentration and chromatographic purification of active fraction of fruit body of tochukaso; 3,5,6-trihydroxy-10,13,14-trimethyl-11-acetoxy-17-(2-(5,6-dimethyl-hept-3 -ene))gonane-3-one
10/15/2002	US6465445 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
10/15/2002	US6465444 Protein tyrosine phosphatases(ptp-1b); antidiabetic, antitumor and anorexigenic agents; combination therapy
10/15/2002	US6465440 Antimutagenic compositions for treatment and prevention of photodamage to skin
10/15/2002	US6465433 Boronic ester and acid compounds, synthesis and uses
10/15/2002	US6465424 Comprising a purified polypeptide the amino acid sequence of which comprises the pre-activation domain from plasminogen and at least one kringle from plasminogen
10/15/2002	US6465422 Method for inhibiting tumor invasion or spreading in a subject
10/15/2002	US6465184 Determining gene expression of nucleic acid encoding tumor rejection antigen precursors
10/15/2002	US6465008 For therapy of tumors
10/15/2002	US6465007 Gene therapy using absorption enhancers or tight junction disrupters; transfection of a biologically active molecule by a cationic amphiphile: biologically active molecule complex or other lipid or viral or nonviral vectors; cystic fibrosis
10/15/2002	US6464980 MAGE-1 c-terminal immunogenic peptides
10/15/2002	US6464973 Universal GM-CSF expressing bystander human K562 cell line
10/15/2002	CA2253795C Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
10/15/2002	CA2091766C Enhancement of glutathione levels with glutamine
10/10/2002	WO2002079517A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
10/10/2002	WO2002079478A2 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
10/10/2002	WO2002079465A2 Micromonospora echinospora genes encoding for biosynthesis of calicheamicin and self-resistance thereto
10/10/2002	WO2002079448A2 G-protein coupled receptors
10/10/2002	WO2002079441A2 Secreted proteins
10/10/2002	WO2002079429A2 Anti-muc-1 single chain antibodies for tumor targeting
10/10/2002	WO2002079417A2 Methods of delivery of exogenous proteins to the cytosol and uses thereof
10/10/2002	WO2002079408A2 Short bioactive peptides and methods for their use
10/10/2002	WO2002079404A2 Cytoskeleton-associated proteins
10/10/2002	WO2002079255A1 RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
10/10/2002	WO2002079253A1 Wti modified peptide
10/10/2002	WO2002079249A2 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
10/10/2002	WO2002079238A2 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis
10/10/2002	WO2002079236A1 Alpha conotoxin peptides with analgesic properties
10/10/2002	WO2002079222A2 Fusion proteins for specific treatment of cancer and auto-immune diseases
10/10/2002	WO2002079219A2 Anti-proliferative 6-o-acyl-beta-d-glucosyl-beta-sitosterol compounds
10/10/2002	WO2002079197A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

1 ... 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 ... 2211